penetrating aortic ulcer
Recently Published Documents


TOTAL DOCUMENTS

107
(FIVE YEARS 47)

H-INDEX

12
(FIVE YEARS 3)

2021 ◽  
Vol 27 (2) ◽  
pp. 106-109
Author(s):  
Misoon Lee ◽  
Dasom Choi ◽  
Bon Sung Koo ◽  
Sung-Hwan Cho

A key challenge of anesthesia is to provide patients with safe and optimized anesthetic management to improve prognosis and minimize mortality and morbidity. To this end, the anesthesiologist should comprehensively understand the patient’s physical status through pre-anesthetic assessment and carefully monitor the patient during surgery. Several types of novel patient-monitoring devices may be useful to achieve this purpose. We report a case of anesthetic management in a patient with left internal carotid artery occlusion and penetrating aortic ulcer.


2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Shixiong Wang ◽  
Debin Liu ◽  
Yongnan Li ◽  
Bingren Gao

AbstractPenetrating aortic ulcer (PAU) is one of the three subtypes of acute aortic syndrome. PAUs occur at any point throughout the aorta, most commonly in the descending thoracic aorta and less frequently in the aortic arch. Open surgical repair and total/hybrid endovascular repair are currently available to treat aortic arch PAUs. Herein, we present a patient with aortic arch PAU who underwent transthoracic minimally invasive closure, which is a novel method for the treatment of PAU. We describe a 52-year old Asian man who presented with sudden chest and back pain for 8 h. Computed tomography angiography showed that the PAU occurred in the aortic arch and had a diameter of 16 mm and a depth of 6 mm. The opening was successfully closed via transthoracic minimally invasive closure with an atrial septal defect occluder.


Circulation ◽  
2021 ◽  
Vol 144 (14) ◽  
pp. 1102-1103
Author(s):  
Yoshikatsu Saiki

2021 ◽  
Vol 3 (14) ◽  
pp. 1617-1621
Author(s):  
Lily K. Stern ◽  
Natasha Cuk ◽  
Paul J. Marano ◽  
Alan C. Kwan ◽  
Evelyn J. Song ◽  
...  

2021 ◽  
Vol 14 (1) ◽  
pp. 88-92
Author(s):  
Abul Hasan Muhammad Bashar ◽  
Humayun Kabir ◽  
Mokhlesur Rahman ◽  
Md Ahsanul Alam

Thoracic Endovascular Aortic Repair (TEVAR) is a state-of-the art endovascular intervention used to treat various thoracic aortic pathologies such as aneurysm, dissection and penetrating aortic ulcers (PAU). The procedure demands significant technical skill and involves considerable cost burden for the patients. The latter is the main reason why the procedure has not yet made it to the routine clinical practice in Bangladesh. We recently performed TEVAR for the successful treatment of an ominous-looking PAU in the descending thoracic aorta in a patient with renal failure. Cardiovasc j 2021; 14(1): 88-92


2021 ◽  
Vol 74 (3) ◽  
pp. e116-e117
Author(s):  
Priya Patel ◽  
Christina Marcaccio ◽  
Livia de Guerre ◽  
Virendra I. Patel ◽  
Marc L. Schermerhorn ◽  
...  

Author(s):  
E. Dinoto ◽  
F. Ferlito ◽  
G. Tortomasi ◽  
S. Evola ◽  
G. Bajardi ◽  
...  

Vascular ◽  
2021 ◽  
pp. 170853812110125
Author(s):  
Xiaolang Jiang ◽  
Yifan Liu ◽  
Bin Chen ◽  
Junhao Jiang ◽  
Yun Shi ◽  
...  

Objectives To identify the differences between clinical features and outcomes after endovascular therapy for penetrating aortic ulcer (PAU) and intramural hematoma (IMH). Methods From January 2009 to March 2020, patients who underwent endovascular therapy for PAU and IMH were enrolled. Information on patient demographics, presentation, PAU and IMH morphology, laboratory examination, and clinical follow-up information was collected and analyzed. Univariate analysis was performed to identify the differences between IMH and PAU, and Kaplan–Meier was used to calculate the cumulative survival rate and freedom from reintervention. Results A total of 114 patients were enrolled; 80 (70.2%) of them were diagnosed with PAU. Compared with PAU, patients with IMH were younger ( p = 0.006), more likely to be admitted emergently ( p = 0.001), had longer hospital stay ( p = 0.028), and had higher levels of C-reactive protein ( p = 0.030). Meanwhile, patients with IMH were more likely to be associated with hypertension ( p = 0.020) and pleural effusion ( p < 0.001) and less likely to have a history of acute coronary syndrome ( p = 0.019) and prior cardiovascular intervention ( p = 0.017). The five-year freedom from reintervention and cumulative survival rate were 94.2% (95% confidential interval, 88.9%–99.9%) and 87.8% (95% confidential interval, 79.5%–96.9%) in PAU patients and 89.6% (95% confidential interval, 75.8%–99.9%) and 85.1% (95% confidential interval, 68.0%–99.9%) in IMH patients, respectively. There was no significant difference in freedom from reintervention ( p = 0.795) or cumulative survival rate ( p = 0.817). Conclusions IMH appeared to occur in younger patients with hypertension and usually had an acute onset, while PAU was more likely to be found incidentally in older patients with atherosclerosis. Endovascular therapy was effective in both IMH and PAU patients with encouraging outcomes.


Sign in / Sign up

Export Citation Format

Share Document